PRCT Healthcare

PROCEPT BioRobotics Corporation

$20.17+3.76%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 1.1B USD
Enterprise value: 830.1M USD
Full-time employees: 888

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.90 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.90 vs peers 0.63)

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.
PROCEPT BioRobotics made a loss per share in its latest year after a profit the year before.
Stock-based pay is a large cost. Stock pay was 15% of revenue in 2025.
PROCEPT BioRobotics paid employees $48M in stock in 2025, 15% of its $308M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Operating margin improving. Operating margin -34% in 2025, the best of the last 6 years, but the dollar loss grew to $104M from $97M.
PROCEPT BioRobotics still lost money on operations in 2025. Revenue grew faster than costs, so the margin (-34%) was its best in the 6 years of filings we have, but the operating loss itself grew to $104M from $97M.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, PROCEPT BioRobotics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

46/ 100

Oct 5 46 → Nov 4 46

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-1.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-11.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-7.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield29.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

78/100

Moderate▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 4.8%

Why it changed since the Oct 27, 2026 close: Score 79 → 78

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth49.2%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 5.16Sector median: 0.0584 · MAD: 0.0840

Revenue growth22.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.70Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

22/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-33.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.36Sector median: 0.0706 · MAD: 0.1217

Return on assets-3.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.87Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-55.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -5.95Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin64.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-4.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.90

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.82Sector median: 0.6250 · MAD: 0.3380

Current ratio6.55×

SEC filings · latest balance sheetReported value33% base weight · Z-score 2.86Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.15×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.34Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about PROCEPT BioRobotics

Is PROCEPT BioRobotics getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 46/100 since Oct 28, 2026.
How is PROCEPT BioRobotics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.2% vs peers 1.5% (weaker than 100% of peers).
Is PROCEPT BioRobotics growing?: Yes, faster than most of its peers. Growth scores 78/100 against 1,393 healthcare peers. 3-year revenue growth 49.2% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 49.2% vs peers 5.8% (stronger than 92% of peers).
How profitable is PROCEPT BioRobotics?: Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital -55.1% vs a peer median of 4.7% (weaker than 89% of peers).Return on invested capital -55.1% vs peers 4.7% (weaker than 89% of peers).
How risky is PROCEPT BioRobotics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 6.55× vs a peer median of 2.59× (stronger than 80% of peers).Current ratio 6.55× vs peers 2.59× (stronger than 80% of peers). Beta 0.90 vs a peer median of 0.63 (weaker than 67% of peers).Beta 0.90 vs peers 0.63 (weaker than 67% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	322.0M USD	337.3M USD	+4.8%
Net income (12 months)	−7.0M USD	−14.3M USD	+104.1%
Operating margin	-33.9%	-33.9%	−0.0 pts
Free cash flow (12 months)	−80.6M USD	−84.9M USD	+5.4%
Debt	51.7M USD	51.7M USD	+0.1%
Cash	245.6M USD	227.9M USD	−7.2%
Shares outstanding	56.9M	57.3M	+0.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	46.0%	49.4%	52.2%	61.1%	63.7%	▲ 2.6 pts
Operating margin	-157.1%	-107.6%	-80.2%	-43.0%	-33.7%	▲ 9.3 pts
Net margin	-173.6%	-116.2%	-77.8%	-40.7%	-31.0%	▲ 9.7 pts
Return on assets (ROA)	-17.8%	-28.2%	-26.2%	-17.1%	-18.8%	▼ 1.7 pts
Return on equity (ROE)	-22.4%	-44.2%	-37.7%	-22.7%	-26.1%	▼ 3.4 pts
Free cash flow margin	-168.0%	-110.7%	-97.8%	-46.2%	-18.9%	▲ 27 pts
Current ratio	20.08×	7.73×	7.63×	9.07×	6.85×	▼ 25%
Quick ratio	19.27×	6.92×	6.77×	8.01×	5.77×	▼ 28%
Debt to equity	0.19×	0.26×	0.18×	0.13×	0.14×	▲ 10%
Interest coverage	-9.32×	-15.57×	-27.33×	-23.09×	-28.96×	▼ 25%

PRCT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.90 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.90 vs peers 0.63)

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.

PROCEPT BioRobotics made a loss per share in its latest year after a profit the year before.

Stock-based pay is a large cost. Stock pay was 15% of revenue in 2025.

PROCEPT BioRobotics paid employees $48M in stock in 2025, 15% of its $308M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Operating margin improving. Operating margin -34% in 2025, the best of the last 6 years, but the dollar loss grew to $104M from $97M.

PROCEPT BioRobotics still lost money on operations in 2025. Revenue grew faster than costs, so the margin (-34%) was its best in the 6 years of filings we have, but the operating loss itself grew to $104M from $97M.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, PROCEPT BioRobotics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about PROCEPT BioRobotics

Is PROCEPT BioRobotics getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 46/100 since Oct 28, 2026.

How is PROCEPT BioRobotics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.2% vs peers 1.5% (weaker than 100% of peers).

Is PROCEPT BioRobotics growing?

Yes, faster than most of its peers. Growth scores 78/100 against 1,393 healthcare peers. 3-year revenue growth 49.2% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 49.2% vs peers 5.8% (stronger than 92% of peers).

How profitable is PROCEPT BioRobotics?

Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital -55.1% vs a peer median of 4.7% (weaker than 89% of peers).Return on invested capital -55.1% vs peers 4.7% (weaker than 89% of peers).

How risky is PROCEPT BioRobotics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 6.55× vs a peer median of 2.59× (stronger than 80% of peers).Current ratio 6.55× vs peers 2.59× (stronger than 80% of peers). Beta 0.90 vs a peer median of 0.63 (weaker than 67% of peers).Beta 0.90 vs peers 0.63 (weaker than 67% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

322.0M USD

337.3M USD

+4.8%

Net income (12 months)

−7.0M USD

−14.3M USD

+104.1%

Operating margin

-33.9%

-33.9%

−0.0 pts

Free cash flow (12 months)

−80.6M USD

−84.9M USD

+5.4%

Debt

51.7M USD

51.7M USD

+0.1%

Cash

245.6M USD

227.9M USD

−7.2%

Shares outstanding

56.9M

57.3M

+0.6%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

46.0%

49.4%

52.2%

61.1%

63.7%

▲ 2.6 pts

Operating margin

-157.1%

-107.6%

-80.2%

-43.0%

-33.7%

▲ 9.3 pts

Net margin

-173.6%

-116.2%

-77.8%

-40.7%

-31.0%

▲ 9.7 pts

Return on assets (ROA)

-17.8%

-28.2%

-26.2%

-17.1%

-18.8%

▼ 1.7 pts

Return on equity (ROE)

-22.4%

-44.2%

-37.7%

-22.7%

-26.1%

▼ 3.4 pts

Free cash flow margin

-168.0%

-110.7%

-97.8%

-46.2%

-18.9%

▲ 27 pts

Current ratio

20.08×

7.73×

7.63×

9.07×

6.85×

▼ 25%

Quick ratio

19.27×

6.92×

6.77×

8.01×

5.77×

▼ 28%

Debt to equity

0.19×

0.26×

0.18×

0.13×

0.14×

▲ 10%

Interest coverage

-9.32×

-15.57×

-27.33×

-23.09×

-28.96×

▼ 25%